Inclusion Criteria:

- Histologically confirmed pure testicular seminoma or ovarian germ cell dysgerminoma

- Histologic documentation of metastatic/recurrent disease not required

- Alpha-fetoprotein level must be normal, unless abnormal level is explained by other
conditions and approved by the study chair

- Clinical stage II or III

- Progressive, refractory, or recurrent disease, meeting at least 1 of the following
criteria:

- Measurable progressive disease

- Biopsy-proven residual disease

- Persistently elevated or rising B-human chorionic gonadotropin (HCG) titers,
defined as at least 2 values above the upper limit of normal (ULN)

- Cisplatin-refractory disease without option of potentially curative therapy, meeting
1 of the following criteria:

- Failed high-dose chemotherapy with peripheral blood stem cell transplantation
(PBSCT) or autologous bone marrow transplantation (AuBMT)

- Ineligible for or refused PBSCT or AuBMT

- Unlikely to achieve long-term benefit from PBSCT or AuBMT

- Current evidence of metastatic disease

- Unidimensionally measurable target lesions

- At least 20 mm by conventional techniques (e.g., physical examination for
clinically palpable lymph nodes and superficial skin lesions or chest x-ray
for clearly defined lung lesions surrounded by aerated lung)

- At least 10 mm by spiral CT scan or MRI

- If measurable disease is confined to a solitary lesion, then its neoplastic
nature must be confirmed by histology

- Ultrasound may not be used to measure tumor lesions that are not easily
accessible clinically

- Non-measurable/non-target lesions, with HCG at least ULN, including the following:

- Bone lesions

- Pleural or pericardial effusions

- Ascites

- CNS lesions

- Leptomeningeal disease

- Irradiated lesions, unless progression documented after radiotherapy

- Performance status - ECOG 0-2

- Granulocyte count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

- Hemoglobin at least 9 g/dL (transfusion allowed)

- Bilirubin no greater than 1.5 times upper limit of normal (ULN)

- SGOT/SGPT no greater than 2.5 times ULN

- Creatinine no greater than 1.5 times ULN

- No other severe and/or uncontrolled concurrent medical illness

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective barrier contraception during and for 3 months
after study participation

- See Disease Characteristics

- See Disease Characteristics

- At least 4 weeks since prior chemotherapy

- No concurrent chemotherapy

- No concurrent hormonal therapy except steroids for adrenal failure, hormones for
non-disease-related conditions (e.g., insulin for diabetes), or intermittent
dexamethasone as an antiemetic

- See Disease Characteristics

- At least 4 weeks since prior radiotherapy

- Prior radiotherapy to a symptomatic lesion or one that may produce disability (e.g.,
unstable femur) allowed

- No concurrent palliative radiotherapy

- No concurrent grapefruit juice

- No concurrent warfarin for therapeutic anticoagulation (concurrent mini-dose
warfarin [1 mg orally per day] as prophylaxis allowed)